Safety of I.V. nonnitrogen bisphosphonates on the occurrence of osteonecrosis of the jaw: Long-term follow-up on prostate cancer patients - Abstract

INTRODUCTION: The aim of the study was to disclose information about the recently incorporated bisphosphonates therapies used to treat prostate cancer patients and their potential risks because the chemical nature and nitrogen content varies among the available drugs on the market.

PATIENTS AND METHODS: Three hundred twenty-four consecutive prostate cancer patients were submitted to bisphosphonates therapy after antiandrogen treatment was started. Zoledronic acid was administered monthly (n = 45), bimonthly (n = 15), trimonthly (n = 19), and semestrally (n = 15), and monthly intravenous clodronate was administered in an additional 156 cases. Fourteen additional cases switched the drugs during the course of the treatment.

RESULTS: After a median follow-up of 54 ± 24 (control), 63 ± 7 (clodronate), and 54 ± 6 months (zoledronic acid), the only 2 patients (0.6%) who developed osteonecrosis of the jaw (ONJ) occurred in those who switched the drug.

CONCLUSION: This study is the longest and the largest ever reported on bisphosphonates usage in prostate cancer patients. ONJ seems to be exclusively related to nitrogen content bisphosphonates.

Written by:
Rodrigues P, Hering F, Imperio M.   Are you the author?
Urology Clinic, Hospital Beneficência Portguesa of São Paulo, São Paulo, Brazil; Urology Department, Hospital Santa Helena of São Paulo, São Paulo, Brazil.  

Reference: Clin Genitourin Cancer. 2014 Oct 23. pii: S1558-7673(14)00231-6.
doi: 10.1016/j.clgc.2014.10.001


PubMed Abstract
PMID: 25475039

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe